Seeking Alpha

5967241

5967241
Send Message
View as an RSS Feed
View 5967241's Comments BY TICKER:
Latest  |  Highest rated
  • PHOT Price Target Initiation $.70 [View instapost]
    I agree wit you, This same guy had a price target on AMRN which turned out a disaster for many.
    Mar 19 04:56 PM | Likes Like |Link to Comment
  • I Am Gold (IAG) Strong Buy PT $7.50 [View instapost]
    What is your PT for AMRN ? Still sticking to $29 and $35 ?
    Mar 19 04:56 PM | Likes Like |Link to Comment
  • Celsion's Newest Cancer Treatment Adds To Upside [View article]
    I hope you realize how people got burnt with CLSN last time. Then the typical split and now the same cycle will repeat again. I am sure once bitten twice shy should be applied here.
    Feb 14 02:58 AM | 3 Likes Like |Link to Comment
  • While Amarin Continues To Go Rancid, Neptune Will Soar [View article]
    Well if you go by words like te Chairman has a savvy and character and blah then it also applied to JZ (ex AMRN CEO) who had successfully sold Reliant Pharma to GSK. Currently there are too many players in this space, Only time can tell who will succeed. After the AMRN debacle, I wont be betting on this non approved Krill Oil nor will support any of the views expressed in this article. It is way too much of a gamble to bet on this company which already had their factory burnt up and no real explanation for this outcome. Good Luck !
    Jan 12 11:54 PM | Likes Like |Link to Comment
  • Twitter May Be A Good Short [View article]
    Pretty Hilarious statement "Twitter a good short", WS expect it to trade 2x its listing price, It is only a short a month from now and if shorted today/tomorrow be prepared to be burnt badly.
    Nov 7 08:05 AM | 1 Like Like |Link to Comment
  • AMRN: Does The FDA Need To Be Investigated  [View instapost]
    Ok, FDA did REJECT now. Just to clarify it further if you are still doubtful about this outcome.
    Nov 5 02:15 AM | Likes Like |Link to Comment
  • Can Amarin Salvage Its Earnings Call? [View article]
    Hey Steve, BO price has gone up to $35-$40 a share or 30-40 cents a share ? Thanks for the feedback in advance.
    Nov 5 01:14 AM | Likes Like |Link to Comment
  • Short Sarepta: DMD Drug Prognosis Is Dismal [View article]
    Thanks for this article, An FDA rejection is written all over it which makes for a 10x gain on shorting at current levels.
    Oct 30 01:31 PM | Likes Like |Link to Comment
  • Tesla's Path To A Conservative $500 Per Share [View article]
    Please correct the heading, It is worth 50 a share !
    Oct 29 04:27 PM | 1 Like Like |Link to Comment
  • Are Gold Mining Stocks Finally Turning The Corner? [View article]
    You quoted or lets say Merrill Lynch quoted ABX worth $4.60 at $1200. So what is it worth at $1400 which is more realistic by EOY ?
    Oct 21 06:04 PM | Likes Like |Link to Comment
  • Acorda Therapeutics: 40% Upside Potential With Limited Downside Risk [View article]
    What was the reason for today's action ?
    Oct 14 04:37 PM | Likes Like |Link to Comment
  • AstraZeneca well positioned to join cancer immunotherapy race: Reuters [View news story]
    AZN is always a step behind other. Take the example of one of their recent purchases--> OMTH which doesn't have an approved drug, patent or a pipeline. Half a billion thrown into garbage even after knowing that the competitors are already way ahead of them.
    Oct 14 02:45 PM | Likes Like |Link to Comment
  • Aegis confident regarding Vascepa panel vote [View news story]
    Very well said RAM, you have come up trumps on nearly all your predictions. Thanks for the right call again !
    Oct 14 11:41 AM | Likes Like |Link to Comment
  • Analysis of Vascepa's FDA Briefing Documents [View article]
    It might drop a bit further today but come a day after, it will be back in the 6-6.5 range. Going into the ADCOM being a short might turn out to be very expensive and shorts are more aware than anyone else..

    FDA can do anything but it would be very hard to ignore the non-existent side effects of Vascepa + Anchor trials. I am not going to read too much into the briefing documents and the options trading at this point of time rather look forward to ADCOM mins.

    If anything goes wrong, JZ is not left with many options this time around, he will have to take an $8-$10 and let this go.
    Oct 14 06:34 AM | 2 Likes Like |Link to Comment
  • 5 BioPharmas With Near-Term Catalysts [View article]
    Cramer is not an analyst, Americans watch him because of all the drama when he is on stage, let us call him an actor, a bad one !
    Oct 11 09:18 AM | 7 Likes Like |Link to Comment
COMMENTS STATS
88 Comments
78 Likes